P 03. Efficacy of Shuganyiyang Capsules in the treatment of NIH category IIIA prostatitis and concomitant erectile dysfunction
Prostatits

P 03. Efficacy of Shuganyiyang Capsules in the treatment of NIH category IIIA prostatitis and concomitant erectile dysfunction

Peiyu Liang, Haoyong Li, Zhiyan Zhou, Shengxing Wang, Peng Song, Shanji Ou, Haibo Xu, Yi Yan, Shuming He, Xiaohui Peng, Tingyu Li

Department of Urology, The Affiliated Hospital of Hainan Medical College, Haikou 570102, China


Objective: To evaluate the effect of Shuganyiyang Capsules in the treatment of NIH category III A prostatitis with erectile dysfunction (ED).

Methods: Fifty cases diagnosed to have NIH category III A prostatitis with ED were randomized into Shuganyiyang Capsules group (group A, n=35) and control group (group B, n=15). In group A, NIH-Chronic Prostatitis Symptom Index (NIH-CPSI) score was 25.4±9.3 and international index of Erectile Function-5 (IIEF-5) score was 12.2±3.3; Fluoroquinolones were used for 2 weeks and antagonist of α1-adrenoceptors and Non steroidal anti-inflammatory drugs were used for 4 weeks at the same time, then Shuganyiyang Capsules was added for 4 weeks. In group B, NIH-CPSI score was 25.7±9.0 and IIEF-5 score was 12.9±3.5; antagonist of α1-adrenoceptors and non steroidal antiinflammatory drugs were used for 8 weeks. All the cases were evaluated with IIEF-5 and NIH-CPSI at the 4th and 8th weeks after treatment respectively.

Results: At the end of the 4th week, NIH-CPSI score was 14.2±4.4 in group A and 13.5±5.1 in group B, which were significantly decreased compared with pre-treatment in both groups (P<0.01 for both); but there was no statistically significant difference between the 2 groups (P>0.05). IIEF-5 score was 16.3±4.2 in group A and 17.0±4.2 in group B, which were significantly increased compared with pre-treatment in both groups (P<0.01 for both); but there was no statistically significant difference between the 2 groups (P>0.05).The change of scores of NIH-CPSI was not correlated with that of IIEF-5. At the end of 8th week, NIH-CPSI score was 10.3±3.7 and IIEF-5 score was 20.8±4.4 in group A, which were significantly different from those at the end of 4th week (P<0.01 for both). NIH-CPSI score was 13.9±4.6 and IIEF-5 score was 16.1±4.8 in group B, which were not significantly different from those at the end of 4th week (P>0.05 for both). There were significant differences of NIH-CPSI and IIEF-5 scores between the 2 groups (P<0.01 for both). The change of NIH-CPSI score was negatively correlated with that of IIEF-5 in group A (r=–0.95, P<0.01).

Conclusions: For patients with NIH category III A prostatitis with ED, Shuganyiyang Capsules can effectively improve erectile function as well as decrease the NIH-CPSI score, thus in favor of covering from NIH category III A prostatitis.

Key words

Erectile dysfunction; NIH category III A prostatitis; Shuganyiyang Capsule; NIH-CPSI; IIEF-5

DOI: 10.3978/j.issn.2223-4683.2012.s176